Fig 1.（From left to right）Shih-Hsien Chuang (HoneyBear Biosciences, CEO), Edward Wang (HoneyBear Biosciences, Chairman), , Johnsee Lee (Chairman of Taiwan Bio Industry Organization), Pang-Chyr Yang (Academician of Academia Sinica), , Mei-Hua Wang (former Minister of Economic Affairs), Han-Chung Wu (Director of the Biomedical Translation Research Center (BioTReC)), Hsiu-Hui Chen (Acting President of Development Center for Biotechnology (DCB)), Sarina Lin (HoneyBear Biosciences, Vice Chairwoman), , Wei-Chyun Wong (Chairman and CEO of SCI Pharmtech and Mercuries and Associates Holding Group), and MC Ya-Lin Chen gathered to celebrate for HoneyBear Biosciences moving to a new base.
Recognized and Blessed by Many Representatives from Industry, Government, and Academia
HoneyBear Biosciences Inc. (abbreviated as HoneyBear) held a grand relocation welcome party on April 25, 2025, at 2 PM in the NBRP (National Biotechnology Research Park), attracting nearly 200 important guests from the biotechnology, medical, finance, and venture capital sectors. The event was graced by notable figures, including Ms. Wang, Mei-Hua, Independent Director of Taishin Financial Holding Co., Ltd. and the former Minister of Economic Affairs, Prof. Yang, Pang-Chyr, Professor of Department of Internal Medicine of NTUH, Academician of Academia Sinica, and former President of National Taiwan University (NTU), Honorary Chairman, Lee, Johnsee, Taiwan Bio Industry Organization, former President of Industrial Technology Research Institute (ITRI) and former Chairman of Development Center for Biotechnology (DCB), Dr. Wu, Han-Chung, Director of the Biomedical Translation Research Center (BioTReC), Academia Sinica, Dr. Chen, Hsiu-Hui, Acting President of Development Center for Biotechnology (DCB) and many other very important guests, like Dr. Wong, Wei-Chyun, Chairman and CEO of SCI Pharmtech and Mercuries and Associates Holding Group, etc. arrived to send their bless. Prof. Wong, Chi-Huey, the former President of Academia Sinica, due to official duties, could not attend but sent his regards and expectations for HoneyBear Biosciences' bright future! Additionally, A*STAR Innovation & Enterprise Deputy Chief Executive, Prof. Yeo Yee Chia, and Senior Director of PharmBio Bioprocessing Industry Cluster, Ms. Neo Kah Yean, also sent their blessings. Currently, HoneyBear’s very first and innovative Antibody Radionuclide Conjugates (ARC), which is Taiwan's first ARC as well, developed by their unique patented CoNectarTM technology platform is showing exciting preliminary research results that it can provide more precise tumor suppression effects, potentially overcoming current cancer treatment challenges and holding great potential for innovative precision medicine and internationalization.
During the tea party, Dr. Han-Chung praised HoneyBear for recently being awarded the "Best ADC Developer in Taiwan" in the Asia-Pacific region; former Minister Wang Mei-Hua, now an independent director at Taishin Financial Holdings, mentioned that HoneyBear's acquisition of investment support from A*STAR in Singapore is a honorable achievement and a good example of technology transfer from DCB to industry during her tenure as Minister. Academia Sinica Academician Yang Pang-Chyr expressed his expectation that HoneyBear can develop good drugs in the future to benefit more cancer patients and urged them to accelerate their research and development. Dr. Lee Johnsee, Chairman of Taiwan Bio Industry Organization, mentioned about the long-term relationship between him and HoneyBear, he expressed positive affirmation and encouragement in terms of professional and emotional aspects. Finally, Dr. Chen, Hsiu-Hui, Acting President of Development Center for Biotechnology (DCB) expressed she’s proud of HoneyBear's achievements and wished them continued success.
Vice Chairwoman Lin, Sarina shared that the company successfully raised nearly 300 million in funding last November, the funds are fully accelerating the development of the latest ARC, aiming to conduct IND submission in 2026. They have already submitted applications for biopharmaceutical companies, focusing on innovation and aiming to lead the future with a strong management and research team, who have accumulated more than 200 years of operational and research experience, injecting innovative energy into Taiwan's biotechnology industry and aiming to rise to the international stage. CEO Chuang, Shih-Hsien explained the research and development plan, such as the ongoing HB001 project, which is an international collaboration across Taiwan, Singapore's A*STAR, and the University of California, San Francisco (UCSF). The latest results show that by combining antibodies with radioactive isotopes, it can accurately display drug accumulation at tumor sites, potentially developing better tumor suppression and treatment drugs. He also stated that HoneyBear will continue to promote the CoNectarTM technology platform, seek licensing and collaboration opportunities, and work with partners to develop new drugs, while the R&D team will enhance technical breakthroughs and enrich the pipeline to develop the next generation of ADCs. Mr. Chang Ying-Hsin, Managing Director of H&Q Asia Pacific, was invited to give a talk, he shared insights on investment trends and prospects in the future biotechnology industry from an investor's perspective. He noted that HoneyBear’s focus on developing the next generation of ADCs is a key reason for the positive outlook and active investment in the company; he also mentioned that future capital markets are looking at the potential prospects of long-term care, pets, ADC, and cell therapy in biotechnology development. The presentations attracted significant attention and lively discussions among the attendees.
Chairman Wang, Edward led the important decision-making team to be present at the event, demonstrating a consensus and confidence in future development. Vice Chairwoman Lin, Sarina emphasized: "Since entering the park in 2023, HoneyBear Biosciences, relying on a professional and complete management and R&D team and cross-industry collaboration, is confident in developing Taiwan's first ARC, becoming a bridge connecting Taiwan with the international market and creating more value for human health. Of course, this is also the best return for investors."
HoneyBear Biosciences Inc. (abbreviated as HoneyBear) held a grand relocation welcome party on April 25, 2025, at 2 PM in the NBRP (National Biotechnology Research Park), attracting nearly 200 important guests from the biotechnology, medical, finance, and venture capital sectors. The event was graced by notable figures, including Ms. Wang, Mei-Hua, Independent Director of Taishin Financial Holding Co., Ltd. and the former Minister of Economic Affairs, Prof. Yang, Pang-Chyr, Professor of Department of Internal Medicine of NTUH, Academician of Academia Sinica, and former President of National Taiwan University (NTU), Honorary Chairman, Lee, Johnsee, Taiwan Bio Industry Organization, former President of Industrial Technology Research Institute (ITRI) and former Chairman of Development Center for Biotechnology (DCB), Dr. Wu, Han-Chung, Director of the Biomedical Translation Research Center (BioTReC), Academia Sinica, Dr. Chen, Hsiu-Hui, Acting President of Development Center for Biotechnology (DCB) and many other very important guests, like Dr. Wong, Wei-Chyun, Chairman and CEO of SCI Pharmtech and Mercuries and Associates Holding Group, etc. arrived to send their bless. Prof. Wong, Chi-Huey, the former President of Academia Sinica, due to official duties, could not attend but sent his regards and expectations for HoneyBear Biosciences' bright future! Additionally, A*STAR Innovation & Enterprise Deputy Chief Executive, Prof. Yeo Yee Chia, and Senior Director of PharmBio Bioprocessing Industry Cluster, Ms. Neo Kah Yean, also sent their blessings. Currently, HoneyBear’s very first and innovative Antibody Radionuclide Conjugates (ARC), which is Taiwan's first ARC as well, developed by their unique patented CoNectarTM technology platform is showing exciting preliminary research results that it can provide more precise tumor suppression effects, potentially overcoming current cancer treatment challenges and holding great potential for innovative precision medicine and internationalization.
During the tea party, Dr. Han-Chung praised HoneyBear for recently being awarded the "Best ADC Developer in Taiwan" in the Asia-Pacific region; former Minister Wang Mei-Hua, now an independent director at Taishin Financial Holdings, mentioned that HoneyBear's acquisition of investment support from A*STAR in Singapore is a honorable achievement and a good example of technology transfer from DCB to industry during her tenure as Minister. Academia Sinica Academician Yang Pang-Chyr expressed his expectation that HoneyBear can develop good drugs in the future to benefit more cancer patients and urged them to accelerate their research and development. Dr. Lee Johnsee, Chairman of Taiwan Bio Industry Organization, mentioned about the long-term relationship between him and HoneyBear, he expressed positive affirmation and encouragement in terms of professional and emotional aspects. Finally, Dr. Chen, Hsiu-Hui, Acting President of Development Center for Biotechnology (DCB) expressed she’s proud of HoneyBear's achievements and wished them continued success.
Vice Chairwoman Lin, Sarina shared that the company successfully raised nearly 300 million in funding last November, the funds are fully accelerating the development of the latest ARC, aiming to conduct IND submission in 2026. They have already submitted applications for biopharmaceutical companies, focusing on innovation and aiming to lead the future with a strong management and research team, who have accumulated more than 200 years of operational and research experience, injecting innovative energy into Taiwan's biotechnology industry and aiming to rise to the international stage. CEO Chuang, Shih-Hsien explained the research and development plan, such as the ongoing HB001 project, which is an international collaboration across Taiwan, Singapore's A*STAR, and the University of California, San Francisco (UCSF). The latest results show that by combining antibodies with radioactive isotopes, it can accurately display drug accumulation at tumor sites, potentially developing better tumor suppression and treatment drugs. He also stated that HoneyBear will continue to promote the CoNectarTM technology platform, seek licensing and collaboration opportunities, and work with partners to develop new drugs, while the R&D team will enhance technical breakthroughs and enrich the pipeline to develop the next generation of ADCs. Mr. Chang Ying-Hsin, Managing Director of H&Q Asia Pacific, was invited to give a talk, he shared insights on investment trends and prospects in the future biotechnology industry from an investor's perspective. He noted that HoneyBear’s focus on developing the next generation of ADCs is a key reason for the positive outlook and active investment in the company; he also mentioned that future capital markets are looking at the potential prospects of long-term care, pets, ADC, and cell therapy in biotechnology development. The presentations attracted significant attention and lively discussions among the attendees.
Chairman Wang, Edward led the important decision-making team to be present at the event, demonstrating a consensus and confidence in future development. Vice Chairwoman Lin, Sarina emphasized: "Since entering the park in 2023, HoneyBear Biosciences, relying on a professional and complete management and R&D team and cross-industry collaboration, is confident in developing Taiwan's first ARC, becoming a bridge connecting Taiwan with the international market and creating more value for human health. Of course, this is also the best return for investors."
Fig 2. Near 200 top tier and honorable guests from different territories, including biotech, venture capital, industries, government institutes and academia etc. attended the big celebration party for HoneyBear Biosciences moving to a new base.
